Spotlight on New Oncology Drugs: Access, Costs, and Use

Results from the RAINIER trial showed that mipletamig, venetoclax, and azacitidine achieved a complete remission rate of 90% in patients with AML.

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Clara Bodelon, PhD, MS, discussed her recently published study which found that the greatest physical health declines in patients who survived breast cancer stemmed from chemotherapy.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Updated findings from the CENTAURUS study may support the use of daratumumab monotherapy in those with intermediate- or high-risk smoldering myeloma.

In the phase 2 EPOCI1802 trial, atezolizumab monotherapy elicited a cCR rate of 42.1%, an ORR of 65.8%, and a 12-month OS rate of 65.8% in advanced ESCC.